Rubius Therapeutics

OverviewSuggest Edit

Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.

TypePublic
Founded2013
HQCambridge, US
Websiterubiustx.com

Latest Updates

Employees (est.) (Apr 2019)174(+23%)
Job Openings17
Share Price (Sept 2020)$5.5 (+8%)
Cybersecurity ratingBMore

Key People/Management at Rubius Therapeutics

Pablo J. Cagnoni

Pablo J. Cagnoni

Chief Executive Officer, Director
Christina Coughlin

Christina Coughlin

Chief Medical Officer
Andrew Oh

Andrew Oh

Chief Financial Officer
Kris Elverum

Kris Elverum

Senior Vice President, Business Development and Strategy
Tom Wickham

Tom Wickham

Senior Vice President, Discovery
Spencer Fisk

Spencer Fisk

Senior Vice President & Chief Technical Operations Officer
Show more

Rubius Therapeutics Office Locations

Rubius Therapeutics has offices in Cambridge and Smithfield
Cambridge, US (HQ)
399 Binney St #300
Smithfield, US
100 Technology Way
Show all (2)

Rubius Therapeutics Financials and Metrics

Rubius Therapeutics Revenue

USD

Net income (Q2, 2020)

(37.9m)

EBIT (Q2, 2020)

(37.7m)

Market capitalization (18-Sept-2020)

445.0m

Closing stock price (18-Sept-2020)

5.5

Cash (30-Jun-2020)

129.2m

EV

434.8m
Rubius Therapeutics's current market capitalization is $445 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.4m22.0m39.9m57.2m

R&D expense

8.4m21.2m51.8m112.4m

Operating expense total

10.9m43.3m91.7m169.6m

EBIT

(10.9m)(43.3m)(91.7m)(169.6m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.1m5.8m16.3m13.2m13.5m13.8m15.0m12.7m11.6m

R&D expense

3.7m9.7m12.0m14.4m20.9m27.5m33.5m36.2m26.1m

Operating expense total

4.8m15.4m28.2m27.6m34.4m41.3m48.5m48.9m37.7m

EBIT

(4.8m)(15.4m)(28.2m)(27.6m)(34.4m)(41.3m)(48.5m)(48.8m)(37.7m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.8m104.3m307.1m91.9m

Prepaid Expenses

53.0k700.0k

Current Assets

6.9m105.0m414.4m289.3m

PP&E

868.0k2.4m62.8m56.9m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

136.5m116.9m354.8m192.5m141.1m109.6m144.5m129.2m

Prepaid Expenses

838.0k

Current Assets

193.6m182.8m412.5m385.8m366.6m329.8m245.9m244.1m

PP&E

14.3m21.1m39.2m24.6m41.9m52.5m56.4m55.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.0m)(43.8m)(89.2m)(163.5m)

Depreciation and Amortization

118.0k447.0k1.3m3.0m

Accounts Payable

589.0k1.1m4.9m(1.0m)

Cash From Operating Activities

(9.5m)(21.9m)(58.3m)(110.4m)
Quarterly
USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.9m)(15.3m)(44.4m)(62.0m)(32.6m)(72.0m)(119.0m)

Depreciation and Amortization

48.0k227.0k502.0k879.0k661.0k1.4m2.3m1.8m3.6m

Accounts Payable

937.0k452.0k3.0m2.4m(966.0k)(4.7m)3.2m905.0k3.1m

Cash From Operating Activities

(3.1m)(10.9m)(20.8m)(38.6m)(22.9m)(52.7m)(81.5m)(40.0m)(68.6m)
USDFY, 2016

Debt/Equity

6.3 x

Debt/Assets

1.5 x

Financial Leverage

4.1 x
Show all financial metrics

Rubius Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Rubius Therapeutics Online and Social Media Presence

Embed Graph

Rubius Therapeutics News and Updates

Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial

Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity

RTX-240 Investigational New Drug Application for Solid Tumors Cleared by U.S. FDA

Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported third quarter 2019 financial results and pro…

Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress

On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End

Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress

Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019

Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the company will present preclinical data from …
Show more

Rubius Therapeutics Blogs

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting Content Import Tue, 05/12/2020 - 06:01 Rubius Therapeutics Highlights Preclinical…

An Engineered Allogeneic Artificial Antigen-Presenting Red Cell Therapeutic, RTX-321, for HPV16+ Associated Cancers Promotes Antigen-Specific T Cell Activation and Expansion

Shamael R. Dastagir, Xuqing Zhang, Albert Lee, Timothy J. Lyford, Jennifer M. Mellen, Andrea Schmidt, Mary Gribble, Chris Moore, Thomas J. Wickham, and Tiffany F. Chen RTX-321 Audio Introduction Your browser does not support the audio element. The post An Engineered Allogeneic Artificial Antigen-Pre…

Engineered Red Cell Therapeutics as Artificial Antigen Presenting Cells Promote in vitro Expansion of both Naïve and Exhausted CD4+ T Cells

Engineered Red Cell Therapeutics as Artificial Antigen Presenting Cells Promote in vitro Expansion of both Naïve and Exhausted CD4+ T Cells RCT MHC II aAPC Audio Introduction Your browser does not support the audio element. The post Engineered Red Cell Therapeutics as Artificial Antigen Presenting C…

Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing Facility Strong Cash Position CAMBRIDGE,

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors

CAMBRIDGE, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in

Rubius Therapeutics to Announce First Quarter 2020 Financial Results

CAMBRIDGE, Mass. , May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics , Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report first quarter 2020
Show more

Rubius Therapeutics Frequently Asked Questions

  • When was Rubius Therapeutics founded?

    Rubius Therapeutics was founded in 2013.

  • Who are Rubius Therapeutics key executives?

    Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.

  • How many employees does Rubius Therapeutics have?

    Rubius Therapeutics has 174 employees.

  • Who are Rubius Therapeutics competitors?

    Competitors of Rubius Therapeutics include ImCheck Therapeutics, Centivax and MyoTherix.

  • Where is Rubius Therapeutics headquarters?

    Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.

  • Where are Rubius Therapeutics offices?

    Rubius Therapeutics has offices in Cambridge and Smithfield.

  • How many offices does Rubius Therapeutics have?

    Rubius Therapeutics has 2 offices.